Insiders have been trading these 5 stocks: ((RIOT)), ((QBTS)), ((AXP)), ((LOW)) and ((TEVA)). Here is a breakdown of their recent trades and their value.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a significant transaction, EVP & GC William Richard Jackman has offloaded a substantial portion of his holdings in Riot Platforms. Jackman sold 248,168 shares, amounting to a staggering $3,916,091. This move could signal a strategic shift or personal financial decision, but it certainly caught the attention of market analysts who are now speculating on the future performance of Riot Platforms.
D-Wave Quantum also witnessed a notable transaction, with CFO John Markovich selling 150,000 shares valued at $2,504,999. This sale has raised eyebrows among investors, as they ponder the implications of such a significant divestment by a key executive. The market will be closely watching D-Wave Quantum for any further developments or announcements.
American Express saw a massive transaction as well, with Chairman & CEO Stephen Squeri selling 112,272 shares for an impressive $37,033,681. This substantial sale by the top executive has sparked discussions about the company’s strategic direction and Squeri’s confidence in its future growth prospects.
Lowe’s experienced a flurry of activity with two executives selling shares. EVP, Stores Joseph Michael McFarland sold 43,810 shares worth $11,942,207, while EVP & CFO Brandon J Sink sold 8,192 shares for $2,200,125. These transactions have led to speculation about the company’s current valuation and the executives’ outlook on Lowe’s future performance.
In a contrasting move, Teva Pharmaceutical’s Gen Counsel, CCO, & Secretary David R. McAvoy made a purchase, acquiring 1,113 shares valued at $20,980. This buy-in suggests a vote of confidence in the company’s potential, offering a positive signal to investors who may be considering Teva Pharmaceutical as a viable investment opportunity.